Search

Displaying results 5111 - 5120 of 6835 in total
  1. Drug

    Granisetron

    go.drugbank.com/drugs/DB00889
    ApprovedInvestigational

    A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Afimoxifene

    go.drugbank.com/drugs/DB04468
    Investigational

    It is being developed by Ascent Therapeutics.

  3. Drug

    Metiamide

    go.drugbank.com/drugs/DB08805
    Experimental

    It was an intermediate product on the path to developing cimetidine.

  4. Drug

    Brofaromine

    go.drugbank.com/drugs/DB13876
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    2,5-Dimethoxy-4-ethylthioamphetamine

    go.drugbank.com/drugs/DB13940
    Experimental

    2,5-Dimethoxy-4-ethylthioamphetamine (ALEPH-2) is a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Cry5B

    go.drugbank.com/drugs/DB17783
    Experimental

    Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium _Bacillus thuringiensis_.

  7. Drug

    AZD-8186

    go.drugbank.com/drugs/DB15029
    Investigational

    investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by

  8. Drug

    2X-121

    go.drugbank.com/drugs/DB16063
    Investigational

    2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the

  9. Drug

    SR 140333

    go.drugbank.com/drugs/DB05790
    Experimental

    SR 140333 is tachykinin antagonist which has potential to treat diarrhoea due to food allergy or inflammatory bowel disease.

  10. Drug

    Licofelone

    go.drugbank.com/drugs/DB04725
    Experimental

    Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this … Although phase III trials have been successfully completed in OA patients no dates for regulatory submission have yet been given.